Oncotelic Therapeutics, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net
Oncotelic Therapeutics, Inc. (OTLC) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net of -$144.59 thousand for the 12-month period ending 2021-12-31, per its 10-K/A filed 2023-04-20.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet · last filed 2023-04-20
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net for the quarter ending 2021-12-31 was $0.00.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net for the quarter ending 2021-09-30 was $0.00.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net for the quarter ending 2021-06-30 was $0.00.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net for the quarter ending 2021-03-31 was -$144.59K.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net for fiscal 2021 was -$144.59K.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net for fiscal 2020 was -$678.81K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-20 | $0.00 derived: sum of 2 quarters · filed 2023-04-20 | $0.00 derived: sum of 3 quarters · filed 2023-04-20 | -$144.59K 10-K/A · filed 2023-04-20 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-18 | $0.00 derived: sum of 2 quarters · filed 2022-11-18 | -$144.59K 10-Q · filed 2022-11-18 | -$249.59K derived: sum of 4 quarters · filed 2022-11-18 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-22 | -$144.59K 10-Q · filed 2022-08-22 | -$249.59K derived: sum of 3 quarters · filed 2022-08-22 | -$414.59K derived: sum of 4 quarters · filed 2022-08-22 |
| 2021-03-31 | -$144.59K 10-Q · filed 2022-05-23 | -$249.59K derived: sum of 2 quarters · filed 2022-05-23 | -$414.59K derived: sum of 3 quarters · filed 2022-05-23 | -$454.59K derived: sum of 4 quarters · filed 2022-05-23 |
| 2020-12-31 | -$105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15 | -$270.00K derived: sum of 2 quarters · filed 2022-04-15 | -$310.00K derived: sum of 3 quarters · filed 2022-04-15 | -$678.81K 10-K · filed 2022-04-15 |
| 2020-09-30 | -$165.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-22 | -$205.00K derived: sum of 2 quarters · filed 2021-11-22 | -$573.81K 10-Q · filed 2021-11-22 | |
| 2020-06-30 | -$40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-20 | -$408.81K 10-Q · filed 2021-08-20 | ||
| 2020-03-31 | -$368.81K 10-Q · filed 2021-05-24 |